Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

Role of ROS and Nutritional Antioxidants in Human Diseases

Zewen Liu, Zhangpin Ren, Jun Zhang and 4 more

Frontiers in Physiology · 2018 · Review

doi:10.3389/fphys.2018.00477

Abstract

The overproduction of reactive oxygen species (ROS) has been implicated in the development of various chronic and degenerative diseases such as cancer, respiratory, neurodegenerative, and digestive diseases. Under physiological conditions, the concentrations of ROS are subtlety regulated by antioxidants, which can be either generated endogenously or externally supplemented. A combination of antioxidant-deficiency and malnutrition may render individuals more vulnerable to oxidative stress, thereby increasing the risk of cancer occurrence. In addition, antioxidant defense can be overwhelmed during sustained inflammation such as in chronic obstructive pulmonary diseases, inflammatory bowel disease, and neurodegenerative disorders, cardiovascular diseases, and aging. Certain antioxidant vitamins, such as vitamin D, are essential in regulating biochemical pathways that lead to the proper functioning of the organs. Antioxidant supplementation has been shown to attenuate endogenous antioxidant depletion thus alleviating associated oxidative damage in some clinical research. However, some results indicate that antioxidants exert no favorable effects on disease control. Thus, more studies are warranted to investigate the complicated interactions between ROS and different types of antioxidants for restoration of the redox balance under pathologic conditions. This review highlights the potential roles of ROS and nutritional antioxidants in the pathogenesis of several redox imbalance-related diseases and the attenuation of oxidative stress-induced damages.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Malnutrition is a poor prognostic sign in various diseases, and it is considered a major health concern in developing countries. Reactive oxygen species (ROS) are involved in many important cellular activities including gene transcription, signaling transduction, and immune response. Common ROS include hydroxyl radical (•OH), superoxide (O2•–) and hydrogen peroxide (H2O2). An overproduction of ROS can result in oxidative damage to biomolecules such as lipids, proteins, and DNA, which has been implicated in the development of aging as well as various ailments including cancer, respiratory, cardiovascular, neurodegenerative, and digestive diseases. It is reported that the deleterious effects of excess ROS, or oxidative stress (OS), eventually lead to cell death [71]. The body has equipped several mechanisms to counteract the detrimental effects of OS. Antioxidants, either endogenously generated or externally supplied, are capable of scavenging ROS and reducing the oxidation of cellular molecules, thus alleviating OS. Antioxidants obtained from the diet are essential in supplying endogenous antioxidants for the neutralization of OS. Indeed, malnutrition and certain antioxidant deficiencies have been correlated with diseases such as chronic obstructive pulmonary disease (COPD) and Crohn’s disease (CD). A disturbed nutritional and redox balance is frequently observed in these patients. Malnutrition-induced antioxidant deficiency may contribute to increased risks of disease occurrence and poor treatment outcomes. Currently, the clinical awareness of nutritional balance in disease occurrence, progression, and outcomes is limited. An update on the literature review that focuses on the relationship between patients’ nutritional status and disease development is needed. In this review, we will outline the roles of ROS in common OS-associated diseases and aging as well as discuss the effects of nutritional antioxidants as treatments or adjuvants.

Oxidative Stress and Nutritional Status in Respiratory Diseases

Respiratory diseases such as COPD and asthma have been identified as major health problems due to increased prevalence and mortality worldwide. Environmental exposures to air pollutants and cigarette smoke contribute greatly to an increase in OS in COPD (Figure 1). The toxicity of oxidants directly damages alveoli and connective tissues of the lungs, exacerbating the development of COPD. Excessive ROS formation can also activate inflammatory cells, which in turn generate more ROS in the lungs. This process initiates a vicious cycle of chronic inflammation and OS, as seen in COPD. OS is also implicated in the pathophysiology of asthma. Although it remains inconclusive regarding whether increased OS in asthma is a causative factor of the disease or a consequence of inflammation, OS is suggested to play a pivotal role in asthma progression. In bronchial asthma, OS aggravates airway inflammation by activating transcription factors such as nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK), activator protein-1 (AP-1), as well as pro-inflammatory mediators (Figure 1). Moreover, it enhances airway hyper-responsiveness and stimulates mucin secretion, both of which are associated with severe asthma. OS-induced damages in the respiratory system and the reduced antioxidant defenses further lead to an increase in endogenous ROS formation.

In addition to OS, low body mass index (BMI) and malnutrition are suggested to correlate with the severity of COPD. Underweight COPD patients tend to experience more pulmonary damage, exercise intolerance, and increased mortality rates, in comparison to individuals with normal weights. Malnutrition can lead to respiratory muscle mass reduction, which lowers the strength and endurance of these muscles. In addition, decreased intake or availability of dietary antioxidants such as vitamins C and E, carotenoids, and polyphenols, can weaken the antioxidant system and exacerbate disease progression (Figure 1 and Table 1). A dietary pattern that is rich in vegetables, fruits, fish, and whole grains has been associated with improved pulmonary function and a lower risk of COPD. It is suggested that nutritional supplementation enhances respiratory muscle function in malnourished COPD patients, thereby improving their quality of life. For example, reported that high doses of vitamin D supplementation strengthen respiratory muscle function and exercise capacity in individuals with COPD. As the most well-known nutritional antioxidant, vitamin C is capable of reducing oxidative damages and inflammation in the pulmonary system by scavenging excess ROS and activating NF-κB pathway, respectively. Furthermore, melatonin, a powerful antioxidant and a regulator of the sleep-wake cycle, can also attenuate OS-related lung deterioration (Figure 1 and Table 1). These findings support the potential use of nutritional antioxidants as an adjuvant to COPD treatment. Similarly, several observational studies suggest that nutritional antioxidants from diets or supplements can improve asthma control and lung function in asthmatic patients. A systematic review has proposed that there is an inverse association between dietary intake of vitamins A and C and incidence of asthma (Table 1). Vitamin C functions in conjunction with vitamin E to stimulate the regeneration of membrane-bound α-tocopherol from its oxidized states. In addition, dietary carotenoids have been shown to correlate with improved asthma outcomes and lung function.

The linkage between OS and the development of respiratory diseases suggests a pivotal role of nutritional antioxidants. Vulnerable populations include those with deficiency in dietary antioxidants, increased exposure to environmental sources of oxidants, and poor access to nutritional antioxidants. It is important to note that although antioxidants may help to mitigate the progression of respiratory diseases, antioxidant supplements can act as pro-oxidants or OS inducers if consumed at levels that significantly surpass the recommended dietary intake. The potential benefits and risks of nutritional antioxidant supplementation trials in respiratory diseases should be considered on a case-by-case basis. Furthermore, it remains unknown whether OS is a consequence or the causative factor for some pulmonary diseases. Therefore, antioxidant treatment may not be an effective approach to modify disease progression although it may be able to alleviate OS-related symptoms.

Oxidative Stress and Nutritional Status in Cardiovascular Diseases

Cardiovascular diseases (CVD) are the leading cause of mortality in the United States, resulting in nearly one million deaths each year. The majority of CVD is correlated with atherosclerosis development, in which OS play a causal role. Excessive ROS can be generated in vascular cells from NAD(P)H oxidase (Nox), nitric oxide synthases (NOS) uncoupling, and mitochondria, which cause oxidative modifications of low density lipoprotein (LDL). The oxidized LDL (ox-LDL) transported through the arterial lumens induces apoptosis of endothelial cells and smooth muscle cells (SMCs). By taking up ox-LDL, macrophages may transform into foam cells, which secrete growth mediators to attract SMCs into the intima. SMCs can secret extracellular matrix that forms a thin fibrous cap surrounding the fatty streak. With the continuous propagation of SMCs, monocytes, and macrophages, fatty streaks are ultimately converted into more advanced fibrous plaque, potentially leading to vessel occlusion. Further, OS has also been implicated in the development cardiac hypertrophy, ischemic-reperfusion injury, and myocyte apoptosis, all of which may contribute to heart failure.

Considering the implications of ROS in CVD development, numerous studies have been performed to evaluate the effects of nutritional antioxidants in CVD patients. Consumption of fruit and vegetable is found to increase the levels of antioxidants such as carotene and vitamin C in the blood as well as decrease the cholesterol oxidation. Therefore, the potential benefits of fruits and vegetables in CVD have been broadly investigated. In a meta-analysis consisting of 16 prospective cohort studies and 833,234 participants, CVD-related mortality was found to be inversely correlated with fruit and vegetable consumption. Another study involving 2002 patients with coronary atherosclerosis showed that supplementation of natural α-tocopherol (RRR-AT) can significantly reduce the incidence of CVD-related death and non-fatal myocardial infarction (Table 1). However, different results are present suggesting no beneficial effect of vitamin supplementation on CVD mortality or morbidity. For example, a meta-analysis study, which involved 81,788 participants, reported that daily supplementation of either vitamin E at a dose of 50–800 IU or β carotene at a dose of 15–80 mg did not decrease the mortality associated with CVD. Therefore, vitamin E and β carotene may not be the only active constituent of fruits and vegetables that exert cardiovascular protective effects. Instead, other antioxidant compounds such as lycopene and polyphenols could play a more important role in the protection against CVD as will be discussed below. Furthermore, the inconsistency in treatment outcomes are likely associated with antioxidant formulation. Most of the trials reporting inefficacy of vitamin E have used all-racemic α tocopherol, which is a major constituent of synthetic vitamin E. By contrast, RRR-AT, the natural form of vitamin E has been associated with better treatment effects. Thus, further research is needed to address the difference between RRR-AT and all-racemic α tocopherol in terms of their therapeutic efficacy. Additionally, the complicated redox mechanisms of antioxidant are far from clear now. Some of the antioxidant such as vitamin C may exhibit prooxidant properties when administrated at high doses. This could partially explain why some of the trials using antioxidant supplementation failed to show any protective effect.

Lycopene is a natural dietary antioxidant most abundant in tomatoes. An inverse association was found between CVD incidence and consumption of either tomatoes or lycopene. This could be attributed to the protective effects of lycopene against LDL oxidation by inhibiting cholesterol synthesis and improving LDL degradation (Table 1). An early population-based study was conducted to evaluate the relationship between the risk of myocardial infarction and the status of three types of carotenoids including lycopene, α carotene, and β carotene, respectively. It was found that only lycopene had significant protective effects. Therefore, lycopene may be one of the primary contributors that underlie the protective mechanisms of vegetable consumption against CVD. Additionally, polyphenols are the most abundant antioxidants in human diet (∼1 g/d), widespread in fruit, vegetables, coffee, tea, and cereals. Epidemiologic studies found a significantly reduced risk for CVD with higher polyphenol intake (Table 1). Beverages rich in flavonoid such as tea can markedly improve endothelial function. However, tea consumption did not reduce the oxidative markers in the blood. So it remains elusive whether this beneficial effect of tea is elicited by its antioxidant effects. Indeed, increasing evidence has suggested that the protective effects of polyphenols are not solely contributed by their antioxidant ability but more likely correlated with their anti-inflammatory effects as well as the regulation of vasodilation and apoptosis of endothelial cells.

Oxidative Stress and Nutritional Status in Neurodegenerative Disorders

Neurons are particularly vulnerable to OS-induced damage due to their weakened antioxidant defense system, high demand for oxygen consumption, and abundant polyunsaturated fatty acid content in their cell membranes. A growing number of studies indicate that ROS may be generated via different mechanisms and play complex roles in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and spinocerebellar ataxia (SCA). AD is a major cause of dementia in elderly. Although the exact pathogenesis of AD remains elusive, aging-related progressive increase in OS has been considered a chief contributor to the formation of AD lesions. Evidence has suggested that oxidative events occur prior to the onset of plaque pathology and amyloid-β (Aβ) accumulation, which further supports the critical roles of OS in the initiating stage of AD. In AD, OS modulates JNK/p38 MAPK pathways, leading to the accumulation of Aβ and the hyper-phosphorylation of tau proteins. HD is an autosomal dominant inherited disease, which is caused by a mutated expansion of CAG repeat in exon 1 of HD gene and its resulted mutant protein product “huntingtin” (mHtt). OS is not the initiation factor of HD. However, severe OS is a typical feature of HD and may contribute to the increased DNA oxidation in the HD brain. OS-induced mitochondrial dysfunction is commonly observed in HD and the impairment of respiratory chain can exacerbate ROS formation. Furthermore, mitochondrial aconitase, an important tricarboxylic acid (TCA)-cycle enzyme, is significantly impaired in HD. The decline in aconitase activity is thought to be caused by ROS-induced oxidation of Fe-S cluster within aconitase. As a result, OS is responsible for the metabolic defects seen in HD. In HD, OS is also related to decreased expression of glucose transporter (GLUT)-3, which results in the inhibition of glucose uptake and the over-accumulation of lactate. It remains inconclusive whether OS is an initiator or consequence of neurodegeneration in PD. However, excessive ROS production is a critical component of the mechanisms underlying PD progression. Loss of antioxidant defense, especially glutathione (GSH) content is found early in PD although the cause remains unknown. High levels of oxidation of protein, DNA, and lipids are observed in PD. The toxic products from the oxidative damage may lead to neural cell death. In the substantia nigra pars compacta (SNc) of PD patients, reduced activity of Complex I in the mitochondrial respiratory chain contributes to excessive ROS generation and consequently induces the apoptosis of dopaminergic neurons. In ALS, superoxide dismutase (SOD) 1 mutation and mitochondrial degeneration represent one of the major mechanisms underlying ALS pathology. Specifically, significant vacuolar degeneration of mitochondria was observed just before the death of neuron in SOD1 mutant mice, indicating that mitochondrial dysfunction initiates the onset of ALS. Mutant SOD1 has been shown to abnormally interact with mitochondria, leading to cytochrome c release and activation of apoptosis. A decline in antioxidant capability due to SOD1 mutation is potentially associated with motor neuron degeneration. In addition, elevated OS can inhibit neuroprotective IGF-I/AKT pathways, resulting in neuron cell dysfunction. Furthermore, marked mitochondrial alterations caused by OS have been suggested to be involved in the development of SCA.

Considering the complex roles of OS in neurodegenerative disorders, the regulation of cellular ROS levels may represent a potential treatment to impede neurodegeneration and alleviate associated symptoms. Clinical evidence indicates that neurodegenerations can be ameliorated upon proper intake of natural or supplementary antioxidants. On the other hand, a lack of major antioxidants due to malnutrition, which is implicated in various neurodegenerative diseases, can worsen the progress of neurological conditions. For example, vitamin D deficiency has recently emerged as one of the contributing factors leading to aberrant neurological development. Vitamin D is an essential antioxidant that regulates calcium-mediated neuronal excitotoxicity and the induction of neurotransmitters and synaptic structural proteins. suggested that inadequate vitamin D in serum is highly associated with the loss of dopaminergic neurons in PD brains and increased risk of PD. Neurological impairments have also been manifested in individuals with a vitamin B deficiency. Multiple vitamin B (e.g., B1, B3, and folate) deficiencies are implicated in the pathophysiology of numerous neurodegenerative diseases such as PD and AD.

Rutin, resveratrol, and vitamin E, which target ROS-mediated cascades such as JNK and NF-κB, have yielded some positive outcomes in improving neurodegeneration both in vitro and in vivo. In a rat brain, vitamin E was found to be more effective in modulating OS than vitamins A and C. Accordingly, a 2-year administration of vitamin E at a dose of 2000 IU per day has been shown to reduce the functional decline associated with AD. The combination of vitamin E and coenzyme Q10 improves energy generation in some cases of Friedreich ataxia by attenuating OS and restoring mitochondrial function. In addition to vitamins, phytochemicals, another type of bioactive compounds that can be found in fruits and vegetables, exhibit high antioxidant capacity with potential neuroprotective effects against PD. Anthocyanin derived from strawberries possesses anti-oxidative, anti-inflammatory, and anti-apoptotic abilities. It has been reported to alleviate astrogliosis and preserve neuromuscular junctions and muscle function, serving as a possible therapeutic agent for ALS and other neurodegenerative diseases. During AD progression, resveratrol’s potential in protecting neurons from Aβ and OS-induced toxicity shows promising therapeutic applications. Lipoic acid (LA) is shown to enhance GSH generation and deplete lipid peroxide, thus protecting neurons against OS-induced mitochondrial dysfunction (Table 1). Long-term administration of MitoQ, a mitochondria-target antioxidant, also significantly restores mitochondrial functions in Purkinje cells and alleviates SCA1-related symptoms such as motor incoordination.

Numerous studies have been performed to investigate the therapeutic effects of natural antioxidants on neurodegenerative disorders; however, mixed results have been yielded. For instance, despite the seeming effectiveness of vitamin E, a study has showed that vitamin E intake for 5 months failed to elevate vitamin E levels in ventricular cerebrospinal fluid of PD patients. ROS formation is subtly regulated by antioxidant defense systems within the human body. Hence, single antioxidant intake could not be sufficient to resist OS under pathophysiological conditions and could result in cellular damage. In this regard, a combined use of various nutritional antioxidants should be considered. Importantly, the simple dichotomy in redox biology comprised of good antioxidants and bad ROS is regarded as untenable. It is now well accepted that a small amount of ROS is essential to activate redox-sensitive signaling pathways, while excessive ROS can lead to detrimental effects. The different characteristics and sources of ROS may define their specific roles in regulating cellular activities. Numerous studies have stressed the need for a more precise description of the metabolism of ROS in aspects of quantity, reactivity, location, and reaction kinetics. However, most of the exogenously administrated antioxidants are non-selective and distributed uniformly across various parts of the cells or tissues. The lack of specificity of antioxidants may account for their inefficacy in treating OS-related diseases. It is thus imperative that researchers focus on developing novel and targeted antioxidants such as mitoQ and Nox inhibitors to improve the precise therapeutic effects of antioxidants in future studies.

Oxidative Stress and Nutritional Status in Cancer

ROS are involved in all three stages of cancer development, namely initiation, promotion, and progression. In the initiation stage, ROS-induced DNA mutations can accumulate if they are not repaired in cancerous tissues. Excessive ROS production may lead to oncogenic mutation of DNA, potentially contributing to the onset of cancer. In addition, cancer cells are characterized by more ROS production than normal cells due to an altered metabolism and increased energy demand. ROS-induced OS in carcinoma cells may promote cancer growth by triggering cell growth signaling, enhancing tumor resistance to therapies, increasing blood supply to tumors, and promoting metastasis. ROS promote the expansion of cancerous cells by modifying the genes related to apoptosis, cell proliferation and transcription factors. ROS also upregulate antiapoptotic genes and downregulate proapoptotic proteins via PI3K/AKT and ERK/MEK pathways. In the progression stage of cancer development, ROS contribute to the upregulation of matrix metalloproteinases, inhibiting the action of anti-proteases and angiogenesis, eventually leading to metastasis.

A depletion of endogenous antioxidants or a disruption of redox equilibrium may lead to cancer development. Research has shown that 35% of cancer can be prevented by dietary modifications. Fruits and vegetables, which are rich in antioxidants, exert a protective effect against several different types of cancers. Plant foods that contain polyphenols have proven to be effective antioxidant agents for the body. They have been shown to possess anti-cancer activity which is effective against lung, breast, tongue, gastric, larynx, colon, and prostate cancers (Table 1). Fruits containing higher phenolic content have stronger antioxidant properties since they can induce hydroxyl group substitution in the aromatic rings of phenol compounds. Polyphenols induce apoptosis of cancer cells, inhibit proliferation of mutated cells, reduce production of cyclooxygenase-2 (COX-2), and downregulate cancer gene expression. Moreover, nutrients such as vitamins and minerals can reduce cancer risk by eliciting antioxidant action, inhibiting proliferation of cancerous cells, maintaining DNA methylation, and promoting cell-cycle arrest. In individuals previously treated for cancer, a healthy diet rich in fruits and vegetables can modify biologic markers of cancer progression. Healthy plant foods have shown to reduce the risk of death after being diagnosed with breast, head and neck, and rectal cancers. A high vegetable diet has been shown to be effective in reducing breast cancer recurrence for patients on tamoxifen.

Vitamins such as Vitamin A and E have a preventive effect against oral cancer. Selected micronutrients (vitamin D, carnitine, and selenium) have been shown to improve compliance and prognosis, patients’ quality of life, and reduced adverse effects of cancer treatments. However, limited evidence supports the effectiveness of vitamins and minerals in cancer prevention, and such nutritional regimens are not currently recommended for practice in healthy individuals. Additionally, there is a lack of randomized control trials investigating diets and cancer due to difficulty in whole diet interventions as well as ethical issues in the proposed research. Hence, current recommendations are based on the effectiveness of a healthy diet (rich in fruits, vegetables, and grains, and low on red meat and alcohol) and lifestyle on reducing cancer risk.

Oxidative Stress and Nutritional Status in Digestive Diseases

It is well established that intestinal inflammation-associated OS plays an essential role in the pathophysiology of various gastrointestinal (GI) diseases, such as inflammatory bowel diseases (IBD). Although the exact etiology of IBD remains unclear, the underlying pathologies can be partially attributed to excess ROS formation. Due to the presence of food particles, pathogens, or microbiota imbalance, the GI tract may become irritated, generating excess ROS and compromising endogenous antioxidant defenses. OS disrupts the intestinal epithelial barrier and increases intestinal permeability, further exacerbating inflammation (Figure 2). IBD, which is comprised of CD and ulcerative colitis (UC), is characterized by chronic and prominent inflammation associated with OS in the GI tract. Elevated levels of pro-inflammatory mediators such as platelet activating factor (PAF) and leukotriene B4 (LTB4) observed in the mucosal samples from active IBD patients have been shown to trigger the release of cytotoxic reactive oxygen metabolites by overstimulating phagocytes. Moreover, myeloperoxidases are released during the massive infiltration of polymorphonuclear neutrophils and macrophages into the inflamed mucosa, producing hypochlorous acid, a potent oxidizing agent, via the metabolism of H2O2. Other sources of ROS include enzymes such as cyclooxygenase, xanthine oxidase, and 5-lipoxygenase that reside in the intestinal mucosa.

Despite ROS overproduction, a deficiency in dietary and enzymatic antioxidants also contributes to the development of OS. For example, low levels of enzymatic antioxidants and vitamins have been observed in patients with CD, which is partly due to malnutrition. In malnourished IBD patients, the reduced dietary intakes of fruits and vegetables greatly influence the concentration of carotenoid (vitamin A). Vitamin C, which helps to repair and protect mucosal lining against detrimental insults, is depleted in peptic ulcers and gastritis. Notably, the increased incidence of vitamin D deficiency in CD patients is highly associated with skeletal morbidity and a worsened quality of life (Figure 2). Persistent OS can damage the intestinal barrier and increase the permeability of GI epithelium via lipid peroxidation and tight junction disruption. This alters the composition of commensal microbiota in the GI tract and interrupts their ability to establish colonization resistance, thus promoting the invasion of pathogenic bacteria. Such infections further aggravate ROS production and inflammation and potentially increase the risk of inflammatory bowel syndrome.

Considering a strong indication of ROS elevation in IBD and other GI diseases, the adjuvant or treatment potential of antioxidants are largely investigated. Antioxidant applications have been shown to restore redox balance, thereby attenuating intestinal damages and maintaining GI health. For example, studies have shown that CuZn-SOD and 5-aminosalicylic acid effectively alleviate mucosal injuries in CD by scavenging or inducing rapid decomposition of ROS. In a randomized placebo-controlled study, 3 months of oral antioxidant supplementation markedly improved the serum antioxidant status in CD patients in remission. The combination of antioxidants with n-3 fatty acids further attenuated pro-inflammatory activities, thus serving as a potential treatment for CD. Compared to supplements, dietary intakes of antioxidants from natural fruits and vegetables may be a safer approach to avoid overconsumption. Inappropriate antioxidant application can be harmful by scavenging of physiological ROS. Foods rich in micronutrients such as α-tocopherol (vitamin E) and minerals have been reported to be beneficial in alleviating ROS damage. For example, selenium and zinc interact with GPx and SOD, respectively, to combat OS. The combination of selenium and vitamin E has demonstrated protective effects against oxidative damage in the colon of UC rats (Figure 2 and Table 1). Several functional foods may be beneficial for IBD without undesirable effects.

Oxidative Stress and Nutritional Status in Aging

Free radical theory, which was first proposed by Harman in 1956, suggests that aging is process related with progressive and irreversible accumulation of oxidative damage in the cells. A shift of redox balance toward a more oxidized status is noted in aging cells, as indicated by decreased GSH/GSSG ratio. This alteration of redox profile may blunt cellular capability of buffering ROS produced both under physiological conditions and in response to external stress. Excessive ROS accumulation can directly damage DNA, protein, and lipids, which disturbs normal cellular function. Mitochondrial DNA (mtDNA) is particularly susceptible to OS and the mutation of mtDNA has been closely linked with the aging process. It was reported that mice with somatic mtDNA mutation exhibited an earlier onset of aging-related features such as hair loss, osteoporosis, and decreased subcutaneous fat as well as a shorter lifespan. Exposure to high levels of ROS can also accelerate telomere shortening, which ultimately triggers cellular senescence. For example, fibroblast cells cultured under high OS showed increased rate of telomere shortening and a reduced lifespan. Additionally, aging-associated OS could be responsible for the chronic systematic inflammation as commonly seen in the elderly via the activation of NF-κB. NF-κB is a key regulator for inflammatory factors such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6. OS-induced NF-κB signaling is short-lived under normal conditions in contrast to chronic activation during aging. The persistent low-level inflammation could be responsible for the development of age-related diseases such as atherosclerosis, cancer, and dementia.

Aging population are at a higher risk of suffering from malnutrition due to a general decline in body function including decreased metabolic rate, digestive and absorptive capability. Therefore, the elderly are more likely to be affected by diseases associated with nutritional inadequacy. For example, aging-related vitamin D deficiency has been shown to result in bone loss, susceptibility to fracture, and hyperparathyroidism. Therefore, appropriate supplementation with vitamin D can reduce the risk of hip and other fractures in housebound elderly (Table 1). In recent years, focus on the diet has increased due to the diet being an essential source of exogenously obtained antioxidants. It appears that dietary antioxidants have the anti-aging activity by their ability to suppress the generation of free radicals. Cognitive decline represents a major health concern in aging population. A key study by followed over ten thousand women from 1984–2003 to investigate the relationship between their dietary pattern and cognitive function. It was found that women who consumed more green leafy or cruciferous vegetables demonstrated the lowest cognitive decline; while fruit consumption did not affect their cognitive function. Interestingly, higher intake of green and yellow vegetables was also correlated with a slower rate of skin aging in Japanese women after adjustment for age, BMI, smoking status, and sun exposure.

Energy restriction (ER) has recently been put up as a potential way to extend life expectancy. This was partially due to the favorable effects of ER on redox management. In fruit flies, ER diet significantly increased the expression of SOD1 and SOD2 as well as extended lifespan by 16%. Various natural antioxidants, nutraceuticals, and functional foods have been identified as free radical or progressive oxygen hunters. Therefore, functional foods and nutraceuticals which control the antioxidant activity may represent an important role in slowing the aging process. A diet rich in antioxidant has been shown to increase lifespan in animal models. For instance, a diet supplemented blueberry extract was found to markedly improve the lifespan in fruit flies and Caenorhabditis elegans. This was accompanied by an increased expression of SOD and catalase. The prolongevity induced by blueberry extract was not observed in SOD or catalase-mutated fruit flies. These results suggest that the beneficial effects of blueberry to extend lifespan are potentially linked with boosted endogenous antioxidant system. Other nutritional antioxidants including apple polyphenols, black rice anthocyanin extract, and black tea theaflavins all demonstrated prominent prolongevity effects by upregulating the endogenous antioxidant levels in animal models (Table 1). Further research is needed to evaluate the potential effects of natural antioxidants on life expectancy in human beings.

Summary and Prospective

The implication of OS in the etiology of several chronic and inflammatory diseases indicates that antioxidant-based therapy could be promising for these disorders. A therapeutic strategy that increases an individual’s antioxidant capacity may be useful for a long-term treatment. However, many problems remain elusive regarding antioxidant supplements in disease prevention. It remains to be elucidated about the precise roles of ROS in the pathogenesis of various diseases. Current recommendations are based on the intake of a healthy diet (rich in fruits, vegetables, and grains and low on red meat and alcohol) and healthy lifestyle, which has demonstrated the ability to reduce the risk for diseases. Further research is warranted before using antioxidant supplements as an adjuvant therapy. In the meantime, avoiding oxidant sources such as cigarette smoke and alcohol must be considered when taking dietary antioxidants.

Author Contributions

LZ conceptualized and designed the review. ZL, ZR, and JZ summarized the literature and wrote the manuscript. LZ, EK, C-CC, and TZ critically revised the manuscript. TZ prepared the figures and abstract. All authors agreed to be accountable for the content of this work.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 172

  1. 1.

    Aditi A. Graham D. Y. (2012 ). Vitamin C, gastritis, and gastric disease: a historical review and update. 57 2504–2515.

    Not in our library10.1007/s10620-012-2203-7

  2. 2.

    Alastair F. Emma G. Emma P. (2011 ). Nutrition in inflammatory bowel disease. 35 571–580.

    Not in our library10.1177/0148607111413599

  3. 3.

    Allen S. Britton J. R. Leonardi-Bee J. A. (2009 ). Association between antioxidant vitamins and asthma outcome measures: systematic review and meta-analysis. 64 610–619.

    Not in our library10.1136/thx.2008.101469

  4. 4.

    Altenhofer S. Radermacher K. A. Kleikers P. W. Wingler K. Schmidt H. H. (2015 ). Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. 23 406–427.

    Not in our library10.1089/ars.2013.5814

  5. 5.

    Alzoghaibi M. A. (2013 ). Concepts of oxidative stress and antioxidant defense in Crohn’s disease. 19 6540–6547.

    Not in our library10.3748/wjg.v19.i39.6540

  6. 6.

    Ambrose J. A. Barua R. S. (2004 ). The pathophysiology of cigarette smoking and cardiovascular disease: an update. 43 1731–1737.

    Not in our library10.1016/j.jacc.2003.12.047

  7. 7.

    Ames B. N. Wakimoto P. (2002 ). Are vitamin and mineral deficiencies a major cancer risk? 2 694–704.

    Not in our library10.1038/nrc886

  8. 8.

    Anekonda T. S. (2006 ). Resveratrol–a boon for treating Alzheimer’s disease? 52 316–326.

    Not in our library10.1016/j.brainresrev.2006.04.004

  9. 9.

    Arab L. Steck S. (2000 ). Lycopene and cardiovascular disease. 71 1691s–1695s.

    Not in our library10.1093/ajcn/71.6.1691s

  10. 10.

    Arthur A. E. Peterson K. E. Rozek L. S. Taylor J. M. Light E. Chepeha D. B. (2013 ). Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis. 97 360–368.

    Not in our library10.3945/ajcn.112.044859

  11. 11.

    Asplund K. (2002 ). Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. 251 372–392.

    Not in our library10.1046/j.1365-2796.2002.00973.x

  12. 12.

    Azumi H. Inoue N. Ohashi Y. Terashima M. Mori T. Fujita H. (2002 ). Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris - Important role of NAD(P)H oxidase. 22 1838–1844.

    Not in our library10.1161/01.atv.0000037101.40667.62

  13. 13.

    Balmus I. M. Ciobica A. Trifan A. Stanciu C. (2016 ). The implications of oxidative stress and antioxidant therapies in inflammatory bowel disease: clinical aspects and animal models. 22 3–17.

    Not in our library10.4103/1319-3767.173753

  14. 14.

    Barrajon-Catalan E. Fernandez-Arroyo S. Saura D. Guillen E. Fernandez-Gutierrez A. Segura-Carretero A. (2010 ). Cistaceae aqueous extracts containing ellagitannins show antioxidant and antimicrobial capacity, and cytotoxic activity against human cancer cells. 48 2273–2282.

    Not in our library10.1016/j.fct.2010.05.060

  15. 15.

    Bellaver B. Souza D. G. Souza D. O. Quincozes-Santos A. (2014 ). Resveratrol increases antioxidant defenses and decreases proinflammatory cytokines in hippocampal astrocyte cultures from newborn, adult and aged Wistar rats. 28 479–484.

    Not in our library10.1016/j.tiv.2014.01.006

  16. 16.

    Bhattacharyya A. Chattopadhyay R. Mitra S. Crowe S. E. (2014 ). Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. 94 329–354.

    Not in our library10.1152/physrev.00040.2012

  17. 17.

    Bitiren M. Karakilcik A. Z. Zerin M. Ozardali I. Selek S. Nazligul Y. (2010 ). Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. 136 87–95.

    Not in our library10.1007/s12011-009-8518-3

  18. 18.

    Bjelakovic G. Nikolova D. Simonetti R. G. Gluud C. (2004 ). Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. 364 1219–1228.

    Not in our library10.1016/s0140-6736(04)17138-9

  19. 19.
  20. 20.

    Block K. I. Koch A. C. Mead M. N. Tothy P. K. Newman R. A. Gyllenhaal C. (2008 ). Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. 123 1227–1239.

    Not in our library10.1002/ijc.23754

  21. 21.

    Bonnefont-Rousselot D. Collin F. (2010 ). Melatonin: action as antioxidant and potential applications in human disease and aging. 278 55–67.

    Not in our library10.1016/j.tox.2010.04.008

  22. 22.

    Brambilla D. Mancuso C. Scuderi M. R. Bosco P. Cantarella G. Lempereur L. (2008 ). The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. 7:29.

    Not in our library10.1186/1475-2891-7-29

  23. 23.

    Brown N. S. Bicknell R. (2001 ). Hypoxia and oxidative stress in breast cancer - Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. 3 323–327.

    Not in our library10.1186/bcr315

  24. 24.

    Browne S. E. Beal M. F. (2006 ). Oxidative damage in Huntington’s disease pathogenesis. 8 2061–2073.

    Not in our library10.1089/ars.2006.8.2061

  25. 25.

    Brownie S. (2006 ). Why are elderly individuals at risk of nutritional deficiency? 12 110–118.

    Not in our library10.1111/j.1440-172x.2006.00557.x

  26. 26.

    Buffie C. G. Pamer E. G. (2013 ). Microbiota-mediated colonization resistance against intestinal pathogens. 13 790–801.

    Not in our library10.1038/nri3535

  27. 27.

    Buffinton G. D. Doe W. F. (1995 ). Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. 22 131–143.

    Not in our library10.3109/10715769509147535

  28. 28.

    Cachofeiro V. Goicochea M. De Vinuesa S. G. Oubina P. Lahera V. Luno J. (2008 ). Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. 74 S4–S9.

    Not in our library10.1038/ki.2008.516

  29. 29.

    Cho Y. S. Moon H. B. (2010 ). The role of oxidative stress in the pathogenesis of asthma. 2 183–187.

    Not in our library10.4168/aair.2010.2.3.183

  30. 30.

    Chung H. Y. Cesari M. Anton S. Marzetti E. Giovannini S. Seo A. Y. (2009 ). Molecular inflammation: underpinnings of aging and age-related diseases. 8 18–30.

    Not in our library10.1016/j.arr.2008.07.002

  31. 31.

    Comhair S. A. Erzurum S. C. (2010 ). Redox control of asthma: molecular mechanisms and therapeutic opportunities. 12 93–124.

    Not in our library10.1089/ars.2008.2425

  32. 32.

    Cordero-Herrera I. Martin M. A. Bravo L. Goya L. Ramos S. (2013 ). Epicatechin gallate induces cell death via p53 activation and stimulation of p38 and JNK in human colon cancer SW480 cells. 65 718–728.

    Not in our library10.1080/01635581.2013.795981

  33. 33.

    Couto D. Ribeiro D. Freitas M. Gomes A. Lima J. L. Fernandes E. (2010 ). Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine. 15 259–267.

    Not in our library10.1179/135100010x12826446921707

  34. 34.

    Covarrubias-Pinto A. Moll P. Solis-Maldonado M. Acuna A. I. Riveros A. Miro M. P. (2015 ). Beyond the redox imbalance: oxidative stress contributes to an impaired GLUT3 modulation in Huntington’s disease. 89 1085–1096.

    Not in our library10.1016/j.freeradbiomed.2015.09.024

  35. 35.

    Davila D. Torres-Aleman I. (2008 ). Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. 19 2014–2025.

    Not in our library10.1091/mbc.e07-08-0811

  36. 36.

    Dias V. Junn E. Mouradian M. M. (2013 ). The role of oxidative stress in Parkinson’s disease. 3 461–491.

    Not in our library10.3233/jpd-130230

  37. 37.

    Doll R. Peto R. (1981 ). The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. 66 1191–1308.

    Not in our library10.1093/jnci/66.6.1192

  38. 38.

    Emerit J. Pelletier S. Tosoni-Verlignue D. Mollet M. (1989 ). Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn’s disease. 7 145–149.

    Not in our library10.1016/0891-5849(89)90005-1

  39. 39.

    Evatt M. L. Delong M. R. Khazai N. Rosen A. Triche S. Tangpricha V. (2008 ). Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. 65 1348–1352.

    Not in our library10.1001/archneur.65.10.1348

  40. 40.

    Ferreira I. M. Brooks D. White J. Goldstein R. (2012 ). Nutritional supplementation for stable chronic obstructive pulmonary disease. 12:CD000998.

    Not in our library10.1002/14651858.cd000998.pub3

  41. 41.

    Ferreira I. M. Verreschi I. T. Nery L. E. Goldstein R. S. Zamel N. Brooks D. (1998 ). The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. 114 19–28.

    Not in our library10.1378/chest.114.1.19

  42. 42.

    Fitzpatrick A. M. Teague W. G. Holguin F. Yeh M. Brown L. A. Severe Asthma Research Program (2009 ). Airway glutathione homeostasis is altered in children with severe asthma: evidence for oxidant stress. 123 146.e8–152.e8.

    Not in our library10.1016/j.jaci.2008.10.047

  43. 43.

    Forman H. J. Ursini F. Maiorino M. (2014 ). An overview of mechanisms of redox signaling. 73 2–9.

    Not in our library10.1016/j.yjmcc.2014.01.018

  44. 44.

    Fortmann S. P. Burda B. U. Senger C. A. Lin J. S. Whitlock E. P. (2013 ). Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. 159 824–834.

    Not in our library10.7326/0003-4819-159-12-201312170-00729

  45. 45.

    Garewal H. (1995 ). Antioxidants in oral cancer prevention. 62 1410S–1416S.

    Not in our library10.1093/ajcn/62.6.1410s

  46. 46.

    Geerling B. J. Badart-Smook A. Van Deursen C. Van Houwelingen A. C. Russel M. G. Stockbrugger R. W. (2000 ). Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn’s disease in remission: effects on antioxidant status and fatty acid profile. 6 77–84.

    Not in our library10.1097/00054725-200005000-00002

  47. 47.

    George S. M. Ballard-Barbash R. Shikany J. M. Caan B. J. Freudenheim J. L. Kroenke C. H. (2014 ). Better postdiagnosis diet quality is associated with reduced risk of death among postmenopausal women with invasive breast cancer in the women’s health initiative. 23 575–583.

    Not in our library10.1158/1055-9965.epi-13-1162

  48. 48.

    Gilgun-Sherki Y. Melamed E. Offen D. (2001 ). Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. 40 959–975.

    Not in our library10.1016/s0028-3908(01)00019-3

  49. 49.

    Gloria N. F. Soares N. Brand C. Oliveira F. L. Borojevic R. Teodoro A. J. (2014 ). Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines. 34 1377–1386.

    Not in our library

  50. 50.

    Gold E. B. Pierce J. P. Natarajan L. Stefanick M. L. Laughlin G. A. Caan B. J. (2009 ). Dietary pattern influences breast cancer prognosis in women without hot flashes: the women’s healthy eating and living trial. 27 352–359.

    Not in our library10.1200/jco.2008.16.1067

  51. 51.

    Goodman M. Bostick R. M. Kucuk O. Jones D. P. (2011 ). Clinical trials of antioxidants as cancer prevention agents: past, present, and future. 51 1068–1084.

    Not in our library10.1016/j.freeradbiomed.2011.05.018

  52. 52.

    Grober U. Kisters K. Adamietz I. A. (2015 ). Vitamin D in oncology: update 2015. 38 512–516.

    Not in our library

  53. 53.

    Gumral N. Naziroglu M. Ongel K. Beydilli E. D. Ozguner F. Sutcu R. (2009 ). Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. 27 276–283.

    Not in our library10.1002/cbf.1569

  54. 54.

    Hakonen A. H. Goffart S. Marjavaara S. Paetau A. Cooper H. Mattila K. (2008 ). Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. 17 3822–3835.

    Not in our library10.1093/hmg/ddn280

  55. 55.

    Harman D. (1956 ). Aging - a theory based on free-radical and radiation-chemistry. 11 298–300.

    Not in our library10.1093/geronj/11.3.298

  56. 56.

    Harman D. (2006 ). Alzheimer’s disease pathogenesis: role of aging. 1067 454–460.

    Not in our library10.1196/annals.1354.065

  57. 57.

    Heidenreich P. A. Trogdon J. G. Khavjou O. A. Butler J. Dracup K. Ezekowitz M. D. (2011 ). Forecasting the future of cardiovascular disease in the United States a policy statement from the American heart association. 123 933–944.

    Not in our library10.1161/cir.0b013e31820a55f5

  58. 58.

    Holick M. F. Binkley N. C. Bischoff-Ferrari H. A. Gordon C. M. Hanley D. A. Heaney R. P. (2011 ). Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. 96 1911–1930.

    Not in our library10.1210/jc.2011-0385

  59. 59.

    Hoppe P. P. Krennrich G. (2000 ). Bioavailability and potency of natural-source and all-racemic alpha-tocopherol in the human: a dispute. 39 183–193.

    Not in our library10.1007/s003940070010

  60. 60.

    Hornikx M. Van Remoortel H. Lehouck A. Mathieu C. Maes K. Gayan-Ramirez G. (2012 ). Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial. 13:84.

    Not in our library10.1186/1465-9921-13-84

  61. 61.

    Ignarro L. J. Balestrieri M. L. Napoli C. (2007 ). Nutrition, physical activity, and cardiovascular disease: an update. 73 326–340.

    Not in our library10.1016/j.cardiores.2006.06.030

  62. 62.

    Ingraham L. M. Coates T. D. Allen J. M. Higgins C. P. Baehner R. L. Boxer L. A. (1982 ). Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. 59 1259–1266.

    Not in our library

  63. 63.

    Jenner P. (2003 ). Oxidative stress in Parkinson’s disease. 53 S26–S36.

    Not in our library10.1002/ana.10483

  64. 64.

    Jiang L. Diaz P. T. Best T. M. Stimpfl J. N. He F. Zuo L. (2014 ). Molecular characterization of redox mechanisms in allergic asthma. 113 137–142.

    Not in our library10.1016/j.anai.2014.05.030

  65. 65.

    Jones L. W. Demark-Wahnefried W. (2006 ). Diet, exercise, and complementary therapies after primary treatment for cancer. 7 1017–1026.

    Not in our library10.1016/s1470-2045(06)70976-7

  66. 66.

    Kandola K. Bowman A. Birch-Machin M. A. (2015 ). Oxidative stress–a key emerging impact factor in health, ageing, lifestyle and aesthetics. 37(Suppl. 2) 1–8.

    Not in our library10.1111/ics.12287

  67. 67.

    Kang J. H. Ascherio A. Grodstein F. (2005 ). Fruit and vegetable consumption and cognitive decline in aging women. 57 713–720.

    Not in our library10.1002/ana.20476

  68. 68.

    Katakwar P. Metgud R. Naik S. Mittal R. (2016 ). Oxidative stress marker in oral cancer: a review. 12 438–446.

    Not in our library10.4103/0973-1482.151935

  69. 69.

    Khandrika L. Kumar B. Koul S. Maroni P. Koul H. K. (2009 ). Oxidative stress in prostate cancer. 282 125–136.

    Not in our library10.1016/j.canlet.2008.12.011

  70. 70.

    King D. A. Cordova F. Scharf S. M. (2008 ). Nutritional aspects of chronic obstructive pulmonary disease. 5 519–523.

    Not in our library10.1513/pats.200707-092et

  71. 71.

    Kohlmeier L. Hastings S. B. (1995 ). Epidemiologic evidence of a role of carotenoids in cardiovascular-disease prevention. 62 1370–1376.

    Not in our library10.1093/ajcn/62.6.1370s

  72. 72.

    Kohlmeier L. Kark J. D. Gomezgracia E. Martin B. C. Steck S. E. Kardinaal A. F. (1997 ). Lycopene and myocardial infarction risk in the EURAMIC Study. 146 618–626.

    Not in our library10.1093/oxfordjournals.aje.a009327

  73. 73.

    Kregel K. C. Zhang H. J. (2007 ). An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. 292 R18–R36.

    Not in our library10.1152/ajpregu.00327.2006

  74. 74.

    Kris-Etherton P. M. Lichtenstein A. H. Howard B. V. Steinberg D. Witztum J. L. (2004 ). Antioxidant vitamin supplements and cardiovascular disease. 110 637–641.

    Not in our library10.1161/01.cir.0000137822.39831.f1

  75. 75.

    Li Y. Ma C. Qian M. Wen Z. Jing H. Qian D. (2014 ). Butein induces cell apoptosis and inhibition of cyclooxygenase2 expression in A549 lung cancer cells. 9 763–767.

    Not in our library10.3892/mmr.2013.1850

  76. 76.

    Lin M. T. Beal M. F. (2006 ). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. 443 787–795.

    Not in our library10.1038/nature05292

  77. 77.

    Lips P. (2001 ). Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. 22 477–501.

    Not in our library10.1210/edrv.22.4.0437

  78. 78.

    Lodi R. Hart P. E. Rajagopalan B. Taylor D. J. Crilley J. G. Bradley J. L. (2001 ). Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. 49 590–596.

    Not in our library10.1002/ana.1001

  79. 79.

    Madamanchi N. R. Vendrov A. Runge M. S. (2005 ). Oxidative stress and vascular disease. 25 29–38.

    Not in our library10.1161/01.atv.0000150649.39934.13

  80. 80.

    Manikandan R. Beulaja M. Arulvasu C. Sellamuthu S. Dinesh D. Prabhu D. (2012 ). Synergistic anticancer activity of curcumin and catechin: an in vitro study using human cancer cell lines. 75 112–116.

    Not in our library10.1002/jemt.21032

  81. 81.

    Margaritelis N. V. (2016 ). Antioxidants as therapeutics in the intensive care unit: Have we ticked the redox boxes? Pharmacol. Res. 111 126–132.

    Not in our library10.1016/j.phrs.2016.06.004

  82. 82.

    Margaritelis N. V. Cobley J. N. Paschalis V. Veskoukis A. S. Theodorou A. A. Kyparos A. (2016 ). Principles for integrating reactive species into in vivo biological processes: examples from exercise physiology. 28 256–271.

    Not in our library10.1016/j.cellsig.2015.12.011

  83. 83.

    Mariani E. Polidori M. C. Cherubini A. Mecocci P. (2005 ). Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. 827 65–75.

    Not in our library10.1016/j.jchromb.2005.04.023

  84. 84.

    Masoli M. Fabian D. Holt S. Beasley R. Global Initiative for Asthma (GINA) Program (2004 ). The global burden of asthma: executive summary of the GINA Dissemination Committee report. 59 469–478.

    Not in our library10.1111/j.1398-9995.2004.00526.x

  85. 85.

    Maulik N. (2002 ). Redox signaling of angiogenesis. 4 805–815.

    Not in our library10.1089/152308602760598963

  86. 86.

    Mazo N. A. Echeverria V. Cabezas R. Avila-Rodriguez M. Aliev G. Leszek J. (2017 ). Medicinal plants as protective strategies against Parkinson’s Disease. 23 4180–4188

    Not in our library10.2174/1381612823666170316142803

  87. 87.

    McCubrey J. A. Steelman L. S. Chappell W. H. Abrams S. L. Wong E. W. Chang F. (2007 ). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. 1773 1263–1284.

    Not in our library10.1016/j.bbamcr.2006.10.001

  88. 88.

    Miquel J. (2002 ). Can antioxidant diet supplementation protect against age-related mitochondrial damage? 959 508–516.

    Not in our library10.1111/j.1749-6632.2002.tb02120.x

  89. 89.

    Moreira P. I. Zhu X. Wang X. Lee H. G. Nunomura A. Petersen R. B. (2010 ). Mitochondria: a therapeutic target in neurodegeneration. 1802 212–220.

    Not in our library10.1016/j.bbadis.2009.10.007

  90. 90.

    Moreno-Macias H. Romieu I. (2014 ). Effects of antioxidant supplements and nutrients on patients with asthma and allergies. 133 1237–1244; quiz 1245.

    Not in our library10.1016/j.jaci.2014.03.020

  91. 91.

    Mori K. Shibanuma M. Nose K. (2004 ). Invasive potential induced under long-term oxidative stress in mammary epithelial cells. 64 7464–7472.

    Not in our library10.1158/0008-5472.can-04-1725

  92. 92.

    Moura F. A. De Andrade K. Q. Dos Santos J. C. Araujo O. R. Goulart M. O. (2015 ). Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? 6 617–639.

    Not in our library10.1016/j.redox.2015.10.006

  93. 93.

    Mpandzou G. Ait Ben Haddou E. Regragui W. Benomar A. Yahyaoui M. (2016 ). Vitamin D deficiency and its role in neurological conditions: a review. 172 109–122.

    Not in our library10.1016/j.neurol.2015.11.005

  94. 94.

    Muller O. Krawinkel M. (2005 ). Malnutrition and health in developing countries. 173 279–286.

    Not in our library10.1503/cmaj.050342

  95. 95.

    Murphy M. P. (2014 ). Antioxidants as therapies: can we improve on nature? 66 20–23.

    Not in our library10.1016/j.freeradbiomed.2013.04.010

  96. 96.

    Nagata C. Nakamura K. Wada K. Oba S. Hayashi M. Takeda N. (2010 ). Association of dietary fat, vegetables and antioxidant micronutrients with skin ageing in Japanese women. 103 1493–1498.

    Not in our library10.1017/s0007114509993461

  97. 97.

    Navarro-Alarcon M. Cabrera-Vique C. (2008 ). Selenium in food and the human body: a review. 400 115–141.

    Not in our library10.1016/j.scitotenv.2008.06.024

  98. 98.

    Norat T. Scoccianti C. Boutron-Ruault M. C. Anderson A. Berrino F. Cecchini M. (2015 ). European code against cancer 4th edition: diet and cancer. 39(Suppl. 1) S56–S66.

    Not in our library10.1016/j.canep.2014.12.016

  99. 99.

    Pappert E. J. Tangney C. C. Goetz C. G. Ling Z. D. Lipton J. W. Stebbins G. T. (1996 ). Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson’s disease patients: dose-response study and correlations with plasma levels. 47 1037–1042.

    Not in our library10.1212/wnl.47.4.1037

  100. 100.

    Paredes-Lopez O. Cervantes-Ceja M. L. Vigna-Perez M. Hernandez-Perez T. (2010 ). Berries: improving human health and healthy aging, and promoting quality life–a review. 65 299–308.

    Not in our library10.1007/s11130-010-0177-1

  101. 101.

    Pathak S. K. Sharma R. A. Mellon J. K. (2003 ). Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). 22 5–13.

    Not in our library10.3892/ijo.22.1.5

  102. 102.

    Patten D. A. Germain M. Kelly M. A. Slack R. S. (2010 ). Reactive oxygen species: stuck in the middle of neurodegeneration. 20(Suppl. 2) S357–S367.

    Not in our library10.3233/jad-2010-100498

  103. 103.

    Pauwels R. A. Rabe K. F. (2004 ). Burden and clinical features of chronic obstructive pulmonary disease (COPD). 364 613–620.

    Not in our library10.1016/s0140-6736(04)16855-4

  104. 104.

    Pelser C. Arem H. Pfeiffer R. M. Elena J. W. Alfano C. M. Hollenbeck A. R. (2014 ). Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study. 120 1540–1547.

    Not in our library10.1002/cncr.28573

  105. 105.

    Peng C. Wang X. Chen J. Jiao R. Wang L. Li Y. M. (2014 ). Biology of ageing and role of dietary antioxidants. 2014:831841.

    Not in our library10.1155/2014/831841

  106. 106.
  107. 107.

    Pimplikar S. W. Nixon R. A. Robakis N. K. Shen J. Tsai L. H. (2010 ). Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. 30 14946–14954.

    Not in our library10.1523/jneurosci.4305-10.2010

  108. 108.
  109. 109.

    Poulsen H. E. Prieme H. Loft S. (1998 ). Role of oxidative DNA damage in cancer initiation and promotion. 7 9–16.

    Not in our library

  110. 110.

    Proteggente A. R. Pannala A. S. Paganga G. Van Buren L. Wagner E. Wiseman S. (2002 ). The antioxidant activity of regularly consumed fruit and vegetables reflects their phenolic and vitamin C composition. 36 217–233.

    Not in our library10.1080/10715760290006484

  111. 111.

    Quinones M. Miguel M. Aleixandre A. (2013 ). Beneficial effects of polyphenols on cardiovascular disease. 68 125–131.

    Not in our library10.1016/j.phrs.2012.10.018

  112. 112.

    Rao A. V. Agarwal S. (2000 ). Role of antioxidant lycopene in cancer and heart disease. 19 563–569.

    Not in our library10.1080/07315724.2000.1071895

  113. 113.

    Rayman M. P. (2005 ). Selenium in cancer prevention: a review of the evidence and mechanism of action. 64 527–542.

    Not in our library10.1079/pns2005467

  114. 114.

    Reboul E. Richelle M. Perrot E. Desmoulins-Malezet C. Pirisi V. Borel P. (2006 ). Bioaccessibility of carotenoids and vitamin E from their main dietary sources. 54 8749–8755.

    Not in our library10.1021/jf061818s

  115. 115.

    Rego A. C. Oliveira C. R. (2003 ). Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. 28 1563–1574.

    Not in our library10.1023/a:1025682611389

  116. 116.

    Rogers N. M. Seeger F. Garcin E. D. Roberts D. D. Isenberg J. S. (2014 ). Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow. 5:134.

    Not in our library10.3389/fphys.2014.00134

  117. 117.

    Rokayya S. Li C. J. Zhao Y. Li Y. Sun C. H. (2014 ). Cabbage (Brassica oleracea L. var. capitata) phytochemicals with antioxidant and anti-inflammatory potential. 14 6657–6662.

    Not in our library10.7314/apjcp.2013.14.11.6657

  118. 118.

    Romieu I. (2005 ). Nutrition and lung health. 9 362–374.

    Not in our library

  119. 119.
  120. 120.

    Sak K. (2014 ). Site-specific anticancer effects of dietary flavonoid quercetin. 66 177–193.

    Not in our library10.1080/01635581.2014.864418

  121. 121.

    Sano M. Ernesto C. Thomas R. G. Klauber M. R. Schafer K. Grundman M. (1997 ). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. 336 1216–1222.

    Not in our library10.1056/nejm199704243361704

  122. 122.

    Schols A. M. Ferreira I. M. Franssen F. M. Gosker H. R. Janssens W. Muscaritoli M. (2014 ). Nutritional assessment and therapy in COPD: a European respiratory society statement. 44 1504–1520.

    Not in our library10.1183/09031936.00070914

  123. 123.

    Sechi G. Sechi E. Fois C. Kumar N. (2016 ). Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. 74 281–300.

    Not in our library10.1093/nutrit/nuv107

  124. 124.

    Sesso H. D. Buring J. E. Zhang S. M. Norkus E. P. Gaziano J. M. (2005 ). Dietary and plasma lycopene and the risk of breast cancer. 14 1074–1081.

    Not in our library10.1158/1055-9965.epi-04-0683

  125. 125.

    Sharon P. Stenson W. F. (1984 ). Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. 86 453–460.

    Not in our library

  126. 126.

    Shay K. P. Moreau R. F. Smith E. J. Smith A. R. Hagen T. M. (2009 ). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. 1790 1149–1160.

    Not in our library10.1016/j.bbagen.2009.07.026

  127. 127.

    Shinohara M. Adachi Y. Mitsushita J. Kuwabara M. Nagasawa A. Harada S. (2010 ). Reactive oxygen generated by NADPH oxidase 1 (Nox1) contributes to cell invasion by regulating matrix metalloprotease-9 production and cell migration. 285 4481–4488.

    Not in our library10.1074/jbc.m109.071779

  128. 128.

    Sies H. Stahl W. Sevanian A. (2005 ). Nutritional, dietary and postprandial oxidative stress. 135 969–972.

    Not in our library10.1093/jn/135.5.969

  129. 129.

    Soerjomataram I. Oomen D. Lemmens V. Oenema A. Benetou V. Trichopoulou A. (2010 ). Increased consumption of fruit and vegetables and future cancer incidence in selected European countries. 46 2563–2580.

    Not in our library10.1016/j.ejca.2010.07.026

  130. 130.

    Sosa V. Moline T. Somoza R. Paciucci R. Kondoh H. Me L. L. (2013 ). Oxidative stress and cancer: an overview. 12 376–390.

    Not in our library10.1016/j.arr.2012.10.004

  131. 131.

    Sreelatha S. Dinesh E. Uma C. (2012 ). Antioxidant properties of Rajgira (Amaranthus paniculatus) leaves and potential synergy in chemoprevention. 13 2775–2780.

    Not in our library10.7314/apjcp.2012.13.6.2775

  132. 132.

    Stephens N. G. Parsons A. Schofield P. M. Kelly F. Cheeseman K. Mitchinson M. J. (1996 ). Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS). 347 781–786.

    Not in our library10.1016/s0140-6736(96)90866-1

  133. 133.

    Stucki D. M. Ruegsegger C. Steiner S. Radecke J. Murphy M. P. Zuber B. (2016 ). Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ. 97 427–440.

    Not in our library10.1016/j.freeradbiomed.2016.07.005

  134. 134.

    Sun J. Chu Y. F. Wu X. Liu R. H. (2002 ). Antioxidant and antiproliferative activities of common fruits. 50 7449–7454.

    Not in our library10.1021/jf0207530

  135. 135.

    Tang G. W. (2010 ). Bioconversion of dietary provitamin A carotenoids to vitamin A in humans. 91 1468s–1473s.

    Not in our library10.3945/ajcn.2010.28674g

  136. 136.

    Tecklenburg S. L. Mickleborough T. D. Fly A. D. Bai Y. Stager J. M. (2007 ). Ascorbic acid supplementation attenuates exercise-induced bronchoconstriction in patients with asthma. 101 1770–1778.

    Not in our library10.1016/j.rmed.2007.02.014

  137. 137.

    Thomson C. A. Rock C. L. Thompson P. A. Caan B. J. Cussler E. Flatt S. W. (2011 ). Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women’s Healthy Eating and Living Study. 125 519–527.

    Not in our library10.1007/s10549-010-1014-9

  138. 138.

    Trifunovic A. Wredenberg A. Falkenberg M. Spelbrink J. N. Rovio A. T. Bruder C. E. (2004 ). Premature ageing in mice expressing defective mitochondrial DNA polymerase. 429 417–423.

    Not in our library10.1038/nature02517

  139. 139.

    Trueba G. P. Sanchez G. M. Giuliani A. (2004 ). Oxygen free radical and antioxidant defense mechanism in cancer. 9 2029–2044.

    Not in our library10.2741/1335

  140. 140.

    Tsagalioti E. Trifonos C. Morari A. Vadikolias K. Giaginis C. (2016 ). Clinical value of nutritional status in neurodegenerative diseases: What is its impact and how it affects disease progression and management? 21 162–175.

    Not in our library10.1080/1028415x.2016.1261529

  141. 141.

    Turati F. Rossi M. Pelucchi C. Levi F. La Vecchia C. (2015 ). Fruit and vegetables and cancer risk: a review of southern European studies. 113(Suppl. 2) S102–S110.

    Not in our library10.1017/s0007114515000148

  142. 142.
  143. 143.

    Valko M. Rhodes C. J. Moncol J. Izakovic M. Mazur M. (2006 ). Free radicals, metals and antioxidants in oxidative stress-induced cancer. 160 1–40.

    Not in our library10.1016/j.cbi.2005.12.009

  144. 144.

    van Eeden S. F. Sin D. D. (2013 ). Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process. 20 27–29.

    Not in our library10.1155/2013/509130

  145. 145.

    van Hogezand R. A. Hamdy N. A. (2006 ). Skeletal morbidity in inflammatory bowel disease. 41 59–64.

    Not in our library10.1080/00365520600664276

  146. 146.

    Varraso R. Chiuve S. E. Fung T. T. Barr R. G. Hu F. B. Willett W. C. (2015 ). Alternate Healthy Eating Index 2010 and risk of chronic obstructive pulmonary disease among US women and men: prospective study. 350:h286.

    Not in our library10.1136/bmj.h286

  147. 147.

    Vita J. A. (2005 ). Polyphenols and cardiovascular disease: effects on endothelial and platelet function. 81 292s–297s.

    Not in our library10.1093/ajcn/81.1.292s

  148. 148.

    Vivekananthan D. P. Penn M. S. Sapp S. K. Hsu A. Topol E. J. (2003 ). Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. 362 922–922.

    Not in our library10.1016/s0140-6736(03)13637-9

  149. 149.

    Vonzglinicki T. Saretzki G. Docke W. Lotze C. (1995 ). Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts - a model for senescence. 220 186–193.

    Not in our library10.1006/excr.1995.1305

  150. 150.

    Vrieling A. Buck K. Seibold P. Heinz J. Obi N. Flesch-Janys D. (2013 ). Dietary patterns and survival in German postmenopausal breast cancer survivors. 108 188–192.

    Not in our library10.1038/bjc.2012.521

  151. 151.

    Wallace J. L. Chin B. C. (1997 ). Inflammatory mediators in gastrointestinal defense and injury. 214 192–203.

    Not in our library10.3181/00379727-214-44087

  152. 152.

    Wang J. Yang D. Yu Y. Shao G. Wang Q. (2016 ). Vitamin D and sunlight exposure in newly-diagnosed Parkinson’s disease. 8:142.

    Not in our library10.3390/nu8030142

  153. 153.

    Wang X. Ouyang Y. Y. Liu J. Zhu M. M. Zhao G. Bao W. (2014a ). Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. 349:g4490.

    Not in our library10.1136/bmj.g4490

  154. 154.

    Wang X. Wang W. Li L. Perry G. Lee H. G. Zhu X. W. (2014b ). Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. 1842 1240–1247.

    Not in our library10.1016/j.bbadis.2013.10.015

  155. 155.

    Wells P. G. Mccallum G. P. Chen C. S. Henderson J. T. Lee C. J. Perstin J. (2009 ). Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. 108 4–18.

    Not in our library10.1093/toxsci/kfn263

  156. 156.
  157. 157.

    Winter A. N. Ross E. K. Wilkins H. M. Stankiewicz T. R. Wallace T. Miller K. (2017 ). An anthocyanin-enriched extract from strawberries delays disease onset and extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. [Epub ahead of print].

    Not in our library10.1080/1028415x.2017.1297023

  158. 158.

    Winterbourn C. C. Hampton M. B. (2008 ). Thiol chemistry and specificity in redox signaling. 45 549–561.

    Not in our library10.1016/j.freeradbiomed.2008.05.004

  159. 159.

    Wood L. G. Garg M. L. Smart J. M. Scott H. A. Barker D. Gibson P. G. (2012 ). Manipulating antioxidant intake in asthma: a randomized controlled trial. 96 534–543.

    Not in our library10.3945/ajcn.111.032623

  160. 160.

    World Cancer Research Fund/American Institute for Cancer Research (2007 ). Washington, DC: AICR.

    Not in our library

  161. 161.

    Xie Q. Bai Q. Zou L. Y. Zhang Q. Y. Zhou Y. Chang H. (2014 ). Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells. 53 422–431.

    Not in our library10.1002/gcc.22154

  162. 162.

    Yan M. H. Wang X. Zhu X. (2013 ). Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. 62 90–101.

    Not in our library10.1016/j.freeradbiomed.2012.11.014

  163. 163.

    Zaidi S. M. Banu N. (2004 ). Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. 340 229–233.

    Not in our library10.1016/j.cccn.2003.11.003

  164. 164.

    Zandi P. P. Anthony J. C. Khachaturian A. S. Stone S. V. Gustafson D. Tschanz J. T. (2004 ). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. 61 82–88.

    Not in our library10.1001/archneur.61.1.82

  165. 165.
  166. 166.
  167. 167.

    Zhu H. Li Y. R. (2012 ). Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. 237 474–480.

    Not in our library10.1258/ebm.2011.011358

  168. 168.

    Zino S. Skeaff M. Williams S. Mann J. (1997 ). Randomised controlled trial of effect of fruit and vegetable consumption on plasma concentrations of lipids and antioxidants. 314 1787–1791.

    Not in our library10.1136/bmj.314.7097.1787

  169. 169.

    Zuo L. Hemmelgarn B. T. Chuang C. C. Best T. M. (2015a ). The role of oxidative stress-induced epigenetic alterations in amyloid-beta production in Alzheimer’s disease. 2015:604658.

    Not in our library10.1155/2015/604658

  170. 170.

    Zuo L. Motherwell M. S. (2013 ). The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson’s disease. 532 18–23.

    Not in our library10.1016/j.gene.2013.07.085

  171. 171.

    Zuo L. Pannell B. K. Liu Z. (2016 ). Characterization and redox mechanism of asthma in the elderly. 7 25010–25021.

    Not in our library10.18632/oncotarget.7075

  172. 172.

    Zuo L. Zhou T. Pannell B. K. Ziegler A. C. Best T. M. (2015b ). Biological and physiological role of reactive oxygen species–the good, the bad and the ugly. 214 329–348.

    Not in our library10.1111/apha.12515

Cited by papers we hold 14

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.